Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity - USD ($)	Common Stock	Additional Paid-in- Capital	Accumulated Deficit	Accumulated Other Comprehensive Income	Noncontrolling Interests	Total
Balance at Dec. 31, 2021	$ 10,013	$ 283,161,216	$ (63,556,714)	$ (32,501)	$ 7,475,010	$ 227,057,024
Balance (in Shares) at Dec. 31, 2021	100,133,953
Exercise of stock options	$ 195	374,149				374,344
Exercise of stock options (in Shares)	195,152
Stock based compensation		1,422,937				1,422,937
Equity cost		(19,570)				(19,570)
UK Ltd. Restricted Stock (Note 4)
UK Ltd. Restricted Stock (Note 4) (in Shares)	146,853
Noncontrolling interest contribution					2,063,000	2,063,000
Foreign currency translation				(5,863)		(5,863)
Net loss attributable to Noncontrolling interests					(1,257,257)	(1,257,257)
Net loss attributable to stockholders of DocGo Inc. and Subsidiaries			10,629,694			10,629,694
Balance at Mar. 31, 2022	$ 10,208	284,938,732	(52,927,020)	(38,364)	8,280,753	240,264,309
Balance (in Shares) at Mar. 31, 2022	100,475,958
Balance at Dec. 31, 2022	$ 10,241	301,451,435	(28,972,216)	741,206	5,696,725	278,927,391
Balance (in Shares) at Dec. 31, 2022	102,411,162
Exercise of stock options	$ 10	249,705				$ 249,715
Exercise of stock options (in Shares)	96,101					96,101
Equity cost
UK Ltd. Restricted Stock (Note 4)		167,175				167,175
Stock based compensation	$ 42	8,181,549				8,181,591
Stock based compensation (in Shares)	424,911
Ambulnz Health liquidation			70,284			70,284
Noncontrolling interest contribution
Common stock repurchased
Foreign currency translation				243,658		243,658
Net loss attributable to Noncontrolling interests					(453,120)	(453,120)
Net loss attributable to stockholders of DocGo Inc. and Subsidiaries			(3,465,670)			(3,465,670)
Balance at Mar. 31, 2023	$ 10,293	$ 310,049,864	$ (32,367,602)	$ 984,864	$ 5,243,605	$ 283,921,024
Balance (in Shares) at Mar. 31, 2023	102,932,174